Lucentis ranibizumab regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Lucentis ranibizumab from Novartis to treat visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia - an indication the European Commission added to Lucentis' label in July (see BioCentury, July 15). The recommendation is contingent on Novartis providing Lucentis at an undisclosed discount under a patient access scheme. Final guidance is expected next month. ...